STOCK TITAN

Family trust of EyePoint (EYPT) CEO acquires 1,500 company shares

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

EyePoint, Inc. reported an insider-related purchase involving a family trust associated with President and CEO Jay S. Duker. The trust bought 1,500 shares of common stock in an open-market transaction at $13.1492 per share.

After this trade, the family trust holds 100,665 shares of EyePoint common stock, while Duker directly owns 77,752 shares. The shares in the trust are for the benefit of his children, with his spouse serving as trustee, and Duker disclaims beneficial ownership of those trust-held shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duker Jay S.

(Last) (First) (Middle)
C/O EYEPOINT, INC.
480 PLEASANT STREET, SUITE C400

(Street)
WATERTOWN MA 02472

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EyePoint, Inc. [ EYPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/16/2026 P 1,500 A $13.1492 100,665 I By Family Trust(1)
Common Stock 77,752 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Remarks:
/s/ Ron Honig, Attorney-in-Fact 03/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EyePoint (EYPT) disclose in this Form 4?

EyePoint disclosed an open-market purchase of 1,500 common shares by a family trust linked to CEO Jay S. Duker. The shares were bought at $13.1492 each, reflecting a relatively small insider-related accumulation rather than a sale or derivative exercise.

Who effectively made the EyePoint (EYPT) share purchase reported here?

The purchase was made by a family trust associated with Jay S. Duker, not by Duker personally. The trust benefits his children, with his spouse acting as trustee, and Duker formally disclaims beneficial ownership of the trust’s EyePoint common stock holdings.

How many EyePoint (EYPT) shares does the family trust hold after the transaction?

Following the 1,500-share open-market purchase, the family trust holds 100,665 shares of EyePoint common stock. This updated figure reflects only the indirect holdings in the trust and is separate from Jay S. Duker’s directly owned EyePoint share position.

What is Jay S. Duker’s direct EyePoint (EYPT) share ownership after this filing?

After the reported transaction, Jay S. Duker directly owns 77,752 shares of EyePoint common stock. This direct position is distinct from the 100,665 shares held by the family trust, for which he disclaims beneficial ownership under the Form 4 disclosures.

Was the EyePoint (EYPT) insider transaction a buy or a sell?

The reported insider-related activity was a buy, not a sale. The family trust purchased 1,500 EyePoint common shares in an open-market transaction, contributing to a net-buy position of 1,500 shares in this Form 4, with no concurrent reported sales.

Does the EyePoint (EYPT) Form 4 involve any stock options or derivatives?

This Form 4 does not report any option exercises or other derivative transactions. It shows a straightforward open-market purchase of common stock by the family trust, with no derivative positions listed in the derivative transaction or derivativeSummary sections of the filing.
EyePoint

NASDAQ:EYPT

View EYPT Stock Overview

EYPT Rankings

EYPT Latest News

EYPT Latest SEC Filings

EYPT Stock Data

1.10B
77.09M
Biotechnology
Laboratory Analytical Instruments
Link
United States
WATERTOWN